Jones Trading Initiates Coverage On Larimar Therapeutics with Buy Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
Jones Trading has initiated coverage on Larimar Therapeutics with a Buy rating and set a price target of $14.
September 12, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jones Trading has initiated coverage on Larimar Therapeutics with a Buy rating and a price target of $14, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $14 by Jones Trading suggests a positive sentiment towards Larimar Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100